NattoPharma research network awarded EU funding grant

By Emma Jane Cash

- Last updated on GMT

© NattoPharma
© NattoPharma
Norweigan nutritional supplier NattoPharma has been awarded a sought-after EU Horizon 2020 research grant, which will fund vitamin K2 research.

The Horizon 2020 program awarded the innovative training network (ITN) grant to NattoPharma’s International Research Network. It will provide training for 11 early stage researchers in the management of chronic diseases in the field of cardiovascular disease.

The network, which is based at Queen Mary University of London, includes four other academic institutions – the University of Maastricht, University College of Dublin, Ludvig-Maximilians-Universitaet Muenchen, and Karolinska Institutet in Stockholm – as well as the Medical Research Council Technology, an independent life science medical research charity in the UK.

Leon Schurgers, Professor at CARIM, Maastrichts University, said: "The Horizon 2020 research grant is one of the most pretigious grants in Europe. The successful grant assignment and the opportunity to allocate highly qualified researchers to further work on vitamin K research is a great recognition of the vitamin K2 platform by this collaboration so far".

The grant will allow NattoPharma to continue working on the researching and documenting the benefits of menaquinone 7, a vitamin K2 which is branded as MenaQ7 by the company. The company has been working on the benefits of MenaQ7 , alongside Maastricht University since 2004.

As well as the grant, €2.9 million was awarded to EVOLuTION – European Vascular Interventions and Therapeutic Innovation Network – in which NattoPharma participates, in 2015 and is being used to fund two full-time researchers focusing on MenaQ7.

Hogne Vik, NattoPharma’s Chief Medical Officer, said: “The beneficial effects of MenaQ7 on bone and vasculature is what has driven our marketing efforts. Through EVOLuTION, NattoPharma will now have access to two full-time PhD-candidates that will be focused on exploring existing and potential new mechanisms for biological effects and health benefits for menaquinone-7”.

"One of the fundamental outcomes of this grant is the ability for the researchers at the University of Maastricht to continue to pursue basic science regarding the metabolism of calcium. Clearly this group and NattoPharma have significantly supported development of science over the past 8 years, and this is a tremendous burden to take on alone, so we welcome additional funds,"​ Vik added,

Related news

Related products

show more

SABINSA: COMMITTED TO SCIENCE, NATURE, AND HEALTH

SABINSA: COMMITTED TO SCIENCE, NATURE, AND HEALTH

SABINSA | 01-Aug-2019 | Technical / White Paper

Since 1988 Sabinsa has amplified the wisdom of the past using modern science, technology, and quality standards. The founder’s belief that sustainable...

MenaQ7® Partners Benefit From K2 Outreach

MenaQ7® Partners Benefit From K2 Outreach

NattoPharma USA, Inc. | 22-Apr-2019 | Case Study

MenaQ7® K2 as MK-7 provides health benefits for all ages. That is a fact clinically proven by NattoPharma and communicated to practitioners and consumers...

Breakthrough in Women's Health

Breakthrough in Women's Health

Biosearch Life | 08-Apr-2019 | Clinical Study

A new study performed on women with polycystic ovary syndrome (PCOS) and fertility problems has been published in Gynecological Endocrinology. Results...

Related suppliers

2 comments

K2 PLUS

Posted by harry,

K2 PLUS MAGNESIUM AND POTASSIUM IODIDE, REST TO MANAGE MOST ISSUES

Report abuse

K2 SHOULD BE RECOMMENDED TO REPLACE STATINS

Posted by harry,

FOR THE BENEFIT OF ALL

Report abuse

Follow us

Featured Events

View more

Products

View more

Webinars